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Depression is a major health problem for which most patients are not effectively
treated. This problem is further compounded in children and adolescents where only
two antidepressants [both selective serotonin reuptake inhibitors (SSRIs)] are currently
approved for clinical use. Mouse models provide tools to identify mechanisms that might
account for poor treatment response to antidepressants. However, there are few studies
in adolescent mice and none in juvenile mice. The tail suspension test (TST) is commonly
used to assay for antidepressant-like effects of drugs in adult mice. Here we show that
the TST can also be used to assay antidepressant-like effects of drugs in C57Bl/6 mice
aged 21 (juvenile) and 28 (adolescent) days post-partum (P).We found that the magnitude
of antidepressant-like response to the SSRI escitalopram was less in P21 mice than in
P28 or adult mice. The smaller antidepressant response of juveniles was not related to
either maximal binding (Bmax) or afﬁnity (K d) for [3H]citalopram binding to the serotonin
transporter (SERT) in hippocampus, which did not vary signiﬁcantly among ages. Magnitude
of antidepressant-like response to the tricyclic desipramine was similar among ages, as
were B 3max and K d values for [ H]nisoxetine binding to the norepinephrine transporter in
hippocampus. Together, these ﬁndings suggest that juvenile mice are less responsive to
the antidepressant-like effects of escitalopram than adults, but that this effect is not due to
delayed maturation of SERT in hippocampus. Showing that theTST is a relevant behavioral
assay of antidepressant-like activity in juvenile and adolescent mice sets the stage for
future studies of the mechanisms underlying the antidepressant response in these young
populations.
Keywords: antidepressant, selective serotonin reuptake inhibitor, tricyclic, serotonin transporter, norepinephrine
transporter, juvenile, adolescent, depression
INTRODUCTION
Depression is a major public health problem for which most
patients are not effectively treated. This problem is further com-
pounded in children and adolescents by limited pharmacological
treatment options (Bylund and Reed, 2007). The selective sero-
tonin reuptake inhibitor (SSRI) ﬂuoxetine is currently the only
FDA approved treatment for depression in children and ado-
lescents up to 18 years old, and escitalopram is approved for
children and adolescents age 12 and older. Exacerbating the sit-
uation further, children and adolescents respond poorly to these
antidepressants compared with adults (Tsapakis et al., 2008; Het-
rick et al., 2009, 2010). Given the high prevalence of adolescent
depression, affecting 4–8% of the population with an incidence
of 25% by the end of adolescence (Kessler et al., 2001; Bujoreanu
et al., 2011) and, of major concern, the high prevalence of sui-
cide in this young population (the third leading cause of death in
the 15- to 19-year age group; Reed et al., 2008), there is a clear
need to understand the neural mechanisms accounting for these
differences between children and adolescents on the one hand
and adults on the other, with the hope to uncover targets for the
development of more effective treatments. However, despite many
reports showingmarked differences in the antidepressant response
of children and adolescents compared with adults (Bylund and
Reed, 2007; Tsapakis et al., 2008; Hetrick et al., 2009, 2010; Hazell
and Mirzaie, 2013) there is a paucity of studies investigating the
underlying mechanisms. Thus, reasons for the age-dependency of
antidepressant response remain poorly understood.
Animal models are needed to examine the mechanisms under-
lying age-dependent effects of antidepressants. To date, there are
only a few preclinical studies of antidepressants in juvenile and
early adolescent animals, and most have been conducted using
rats. SSRIs were found to reduce time spent immobile in the forced
swim test (FST), an index of antidepressant-like activity, in rats as
young as postnatal day (P) 21 as well as in adults, whereas blockers
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of the norepinephrine (NE) transporter, such as the tricyclic
antidepressant desipramine (DMI), were ineffective in the FST
in rats younger than P28 (Pechnick et al., 2008; Reed et al., 2008).
The mechanistic basis for these ﬁndings remains to be determined,
but is thought to involve the delayed maturation of the NE neu-
rotransmitter system relative to the serotonin (5-HT) system. In
terms of the actual drug targets themselves, i.e., the serotonin and
norepinephrine transporters (SERT and NET, respectively), infor-
mation about their expression in juvenile and adolescent animals is
sparse. Using quantitative autoradiography, Galineau et al. (2004)
reported a triphasic proﬁle for SERT in amygdala and hypothala-
mus of rats where expression peaked around P21, decreased at P28
and plateaued through P70, the oldest age tested (see also Daws
andGould, 2011). ForNET,Sanders et al. (2005) also using autora-
diography, reported that expression of NET in some brain regions
(e.g., locus coeruleus) was much greater in rats aged P20 than in
adults, while in other regionsNETexpression inP20 ratswas either
less than (e.g., CA3 region of hippocampus) or similar (e.g., cor-
tex, CA1 and CA2 regions of hippocampus, dentate gyrus) to that
of adult rats. Thus, it is not clear from studies in rats, if expres-
sion or activity of SERT and NET correlates positively with the
emergence of an antidepressant-like response to SSRIs and NET
blockers.
Lacking are studies in mice to probe the mechanistic basis
underlying differences in antidepressant-efﬁcacy among juveniles,
adolescents, and adults. The relative ease with which mice can be
geneticallymanipulatedmakes themapowerful tool for preclinical
research. However, there are few studies that have used adolescent
(≥P28) mice to investigate antidepressant-like response (Bourin
et al., 1998; David et al., 2001a; Mason et al., 2009) and none that
have used mice younger than P28. Although mice have been used
to examine the consequences of antidepressant treatment during
prenatal, early postnatal and adult periods, juvenile and adolescent
periods remain largely unexplored. Likewise, little is known about
SERT and NET expression during these juvenile and adolescent
periods in mice.
The tail suspension test (TST) is a preclinical test with good
predictive validity that has become one of the most widely used
models for assessing antidepressant-like activity in adult mice
(Cryan et al., 2005). Currently there is only one report of its use
in adolescent (P35) mice. Thus, it is unknown if the TST can be
used to detect antidepressant-like effects of drugs in early adoles-
cent (P28) and juvenile (P21) mice. The goals of the present study
were twofold: ﬁrst, to examine if the TST can be used to mea-
sure antidepressant-like activity in P21 and P28 mice; and second,
to begin to examine the relationship between antidepressant-like
activity and the expression and afﬁnity of hippocampal SERT and
NET in juvenile, adolescent, and adult mice.
MATERIALS AND METHODS
ANIMALS
Juvenile (P21), early adolescent (P28), and adult (P62–90) male
and female C57Bl/6 mice were obtained from an in house breed-
ing colony (breeding pairs originally obtained from Jackson Lab).
Body weights for male mice ranged from 6.6 to 9.8 g for P21,
from 9.7 to 18.5 g for P28, and from 23.7 to 42.8 g for adults,
and body weights for female mice ranged from 6.3 to 10.0 g for
P21, from 10.8 to 15.1 g for P28, and from 19.1 to 31.3 g for
adults. Animals were housed in a temperature-controlled (24◦C)
vivarium maintained on a 14/10-h light/dark cycle (lights on at
07:00, experiments conducted during the light period) in plas-
tic cages (29 cm × 18 cm × 13 cm) containing rodent bedding
(Sani-chips, Harlan Teklad, Madison,WI,USA) with free access to
food (Rodent sterilizable diet, Harlan Teklad, Madison, WI, USA)
and water. After weaning on postnatal day 21,mice were housed in
groups of ﬁve with same-sex peers. All procedures were conducted
in accordance with the National Institute of Health Guide for the
Care and Use of Laboratory Animals (Institute of Laboratory Ani-
mal Resources, Commission on Life Sciences, National Research
Council 1996), and with the Institutional Animal Care and Use
Committee, The University of Texas Health Science Center at San
Antonio.
TAIL SUSPENSION TEST
The TST was conducted based on the original description by Steru
et al. (1985) [for a review, see (Castagne et al., 2011)]. On the day
before testing,miceweremoved from the colony roomand housed
overnight in a holding room adjoining the procedure room. On
the test day, mice were placed in the procedure room and allowed
1–2 h to acclimate before receiving an injection of saline vehi-
cle (subcutaneously [sc] or intraperitoneally [ip]), escitalopram
(10 mg/kg, sc), or DMI (32 mg/kg, ip). Routes of drug adminis-
tration were based on results in adult mice reported by Cryan et al.
(2005) and Sanchez et al. (2003). Each mouse was tested only once
(i.e., not given multiple drugs nor exposed to the TST on multiple
occasions). Drugs or saline were injected 30 min before testing.
Immediately before testing, the distal end of the tail was fastened
to a ﬂat aluminum (2 × 0.3 × 10 cm) bar using adhesive tape
at a 90◦ angle to the longitudinal axis of the mouse tail and the
aluminum bar, with a distance of 3–4 cm between the base of the
tail and the edge of the bar. A hole opposite the taped end of the
bar was used to secure the bar to a hook in the ceiling of a visually
isolated white test box (40 cm × 40 cm × 40 cm). Each mouse was
suspended by its tail for 6 min, allowing the ventral surface and
front and hind limbs to be video-recorded using a digital camera
facing the test box. Total time immobile was measured (in sec-
onds) during the entire 6 min test period. Immobility was deﬁned
as the absence of initiated movements, and included passive sway-
ing of the body. A mouse was excluded from the experiments if it
climbed and held on to its tail or the aluminum bar for a period
of 3 s or longer. In the present study no mice aged P21 or P28
were excluded. Approximately 5% of adult mice were excluded.
Immobility was scored manually by observers watching the video
and who were blind to the treatment. Typically two observers
scored each videotape with excellent inter-observer agreement
(r2 > 0.9).
Initial experiments were designed to examine the utility of the
TST in juvenile and adolescent mice. Male and female mice were
given either a sc or ip injection of saline, corresponding to the
route of administration for escitalopram and DMI, respectively.
The purpose of these initial experiments was to identify possible
effects of age, gender, and route of administration, as well as any
interactions among these factors, on immobility in the TST. Age
affected basal immobility, and did so in a similar manner in both
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genders after both routes of administration (see Results). Subse-
quent experiments investigated the two reference antidepressant
drugs, escitalopram (10 mg/kg, sc) and DMI (32 mg/kg, ip), in
male mice. Drug doses were selected based on preliminary data
obtained in our laboratory that showed these doses to be the low-
est to produce maximal effects on immobility in adult C57Bl/6J
mice.
[3H]CITALOPRAM AND [3H]NISOXETINE SATURATION BINDING IN
HIPPOCAMPAL HOMOGENATES
All binding experiments were carried out using tissue from male
C57Bl/6 mice.
[ 3H]citalopram binding to SERT
Saturation binding of [3H]citalopram in membrane homogenate
preparations from mouse hippocampi was carried out following
the methods of D’Amato et al. (1987) with minor modiﬁcations.
Brieﬂy, male mice were decapitated, the brain removed and
hippocampi collected. Hippocampi from individual mice were
homogenized in 25 ml of 4◦C 50 mM Tris, 120 mM NaCl, 5 mM
KCl buffer (pH 7.4 at 25◦C), at 2600 rpm on a Polytron tissue
homogenizer (Brinkman Instruments, Westbury, NY, USA). The
homogenate was centrifuged for 10 min at 30,600 × g at 4◦C.
The supernatant was discarded, and the pellet re-suspended on ice
using a Potter Elvehjem glass and Teﬂon homogenizer in 25 ml
ice-cold buffer. The homogenate was re-centrifuged for 10 min at
30,600 × g. The ﬁnal pellet was re-suspended to yield a protein
concentration of approximately 0.5–1.2 μg/μl. Protein was quan-
tiﬁed spectrophotometrically on a plate reader (SpectraMax 190,
Molecular Devices, Sunnyvale, CA, USA) using Bradford reagent
(Sigma, St. Louis, MO, USA). Binding assays were run in trip-
licate for each hippocampal membrane homogenate preparation.
Homogenateswere incubated at 25◦Cfor 1h inbuffer (50mMTris,
120 mM NaCl, 5 mM KCl) containing 0.1–10 nM [3H]citalopram
(Perkin Elmer). Non-speciﬁc binding was deﬁned by addition of
10 μM sertraline (Pﬁzer). Incubation was terminated by addi-
tion of 4 ml of ice cold buffer and rapid ﬁltration under vacuum
onto Whatman GF/B ﬁlter paper strips (Brandel, Gaithersburg,
MD, USA) pre-soaked in 5% polyethyleneimine (Sigma). Filters
were washed twice and radioactivity trapped on the ﬁlters was
measured by liquid scintillation counting using a Beckman 6500
(Beckman, Brea, CA, USA) with efﬁciencies of 40–65%. Bind-
ing data were analyzed by non-linear regression using GraphPad
Prism 5.04.
[ 3H]nisoxetine binding to NET
Saturation binding of [3H]nisoxetine in membrane homogenate
preparations from mouse hippocampi was carried out following
the methods of Tejani-Butt (1992). Hippocampal homogenate
preparation for [3H]nisoxetine binding was as described for [3H]
citaloprambinding, except that hippocampiwere pooled from two
mice to yield protein concentrations of 1.0–1.7 μg/μl, the buffer
was pH 7.4 at 4◦C and the ﬁnal washed pellet was re-suspended in
50 mM Tris, 300 mM NaCl, 5 mM KCl (pH 7.4 at 4◦C). Binding
assays were carried out for 4 h at 4◦C in 50 mM Tris, 300 mM
NaCl, 5 mM KCl at the same volumes used for [3H] citalopram
binding. [3H] nisoxetine concentration ranged from 0.5 to 30 nM
for the saturation assays. Non-speciﬁc binding was deﬁned with
10μM mazindol (Sigma, St Louis, MO,USA). Data collection and
analysis were the same as described for [3H]citalopram binding.
STATISTICAL ANALYSIS
Statistical analyses were performed using Prism 5.04 (GraphPad,
San Diego, CA, USA) and NCSS 2007 (Kaysville, UT, USA). TST
data were analyzed using ANOVA, followed by Tukey’s multiple
comparison tests. Binding data were analyzed using Kruskal–
Wallis test because of signiﬁcant differences in standard deviations
among age groups (Bartlett’s test). All data are expressed as
mean ± standard error of the mean (SEM), and P < 0.05 was
considered statistically signiﬁcant.
DRUGS
Escitalopram oxalate [Shanco International Inc. (Hazlet, NJ,
USA)] and DMI hydrochloride [Sigma-Aldrich (St. Louis, MO,
USA)] were dissolved in physiological saline. Escitalopram was
injected sc at doses expressed as base per kilogram body weight
(Sanchez et al., 2003). DMI was injected ip at doses expressed as
salt per kilogram body weight. The injection volume was 10 ml/kg.
RESULTS
USE OF THE TST IN JUVENILE AND ADOLESCENT MICE
The TST is a preclinical test with good predictive validity that
is widely used to detect antidepressant-like activity (Cryan and
Holmes, 2005; Cryan et al., 2005), and that has been used in mice
as young as P35 (Mason et al., 2009). Antidepressant-like activity
in this test is deﬁned by the ability of a drug to reduce the time a
mouse spends immobile. We ﬁrst examined if the TST could be
used in P21 and P28 mice, given the possibility that young mice
may display so little baseline immobility that the effect of a drug
to reduce immobility further may not be detectible. To this end,
six separate groups of mice (male and female, n = 20 of each
gender and each age, P21, P28, or adult) received an injection of
saline either sc or ip (n = 10 of each gender and age receiving
saline sc, and n = 10 of each gender and age receiving saline ip)
and time spent immobile in a 6 min test was quantiﬁed. There
was no signiﬁcant effect of gender or route of administration on
immobility time, a ﬁnding that is consistent with reports for adult
mice (e.g., David et al., 2001b; Jones and Lucki, 2005; Andreasen
and Redrobe, 2009). There was however, a signiﬁcant effect of age
[F(2, 119) = 6.63, P < 0.0025]. Because there were no signiﬁ-
cant interactions among age, gender, and route of administration,
data were collapsed with age as the only variable (Figure 1). P21
mice spent signiﬁcantly less time immobile (99 ± 8 s) than P28
(123 ± 7 s) or adult mice (135 ± 6 s), and P28 mice did not
differ signiﬁcantly from adults. A factor that might contribute to
reduced immobility time in P21 mice is their smaller size. Regres-
sion analyses of immobility time as a function of body weight for
all ages and both genders, inclusive, revealed an overall positive
correlation (r = 0.24, P < 0.01). However, regression analyses
within each age group revealed no signiﬁcant correlation between
body weight and immobility time (P21, r = −0.12, P = 0.46; P28,
r = 0.23, P = 0.11; adult, r = 0.05, P = 0.66, data not shown).
These data show that juvenile and adolescent mice spend suf-
ﬁcient time immobile in the TST that detection of a drug effect
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FIGURE 1 | Immobility time in theTST as a function of age. Juvenile
mice (P21) spent signiﬁcantly less time immobile than either adolescent
(P28) or adult mice (P > 62). Each age group consisted of 40 animals
treated with saline (20 males and 20 females, half of them treated sc and
the other half ip). Because there were neither main nor interaction effects
of gender and route of administration, data are shown collapsed with age
as the only factor. *P < 0.05, **P < 0.01 (Tukey post hoc test). Data are
mean and SEM.
to decrease immobility should be possible. To test this, juvenile
and adolescent mice were treated acutely with either escitalo-
pram (sc) or DMI (ip), two antidepressants known to produce
robust effects in the TST in adult mice (Sanchez et al., 2003;
O’Leary et al., 2007).
REFERENCE ANTIDEPRESSANTS REDUCE IMMOBILITY ACROSS AGES
Escitalopram (10 mg/kg, sc) and DMI (32 mg/kg, ip) reduced
immobility time in the TST in all age groups [F(1, 51) = 66.45,
P < 0.01] (Figure 2). However, the extent to which they decreased
immobility differed among the age groups. For escitalopram there
was a signiﬁcant interaction between treatment and age [F(2,
51) = 5.08, P < 0.01] because escitalopram reduced immobil-
ity less in P21 mice than in P28 and adult mice. For DMI there
was a signiﬁcant effect of age [F(2, 51) = 7.14, P < 0.01] and DMI
tended to reduce immobility more in P21 and P28 mice than in
adults, but the interactionbetween treatment and age didnot reach
statistical signiﬁcance. Sample sizes for saline-, escitalopram-, and
DMI-treated mice, respectively, were 20, 8, and 10 for mice aged
P21; 20, 8, and 8 formice agedP28, and 20, 10, and 9 for adultmice.
The larger sample size for saline-treatedmice is due to pooling data
from male mice injected with saline sc (n = 10) and ip (n = 10)
for each age. These results show that the TST can be used to exam-
ine antidepressant-like drug effects in mice as young as P21. Next
we investigated the relationship between the antidepressant-like
effects of escitalopram and DMI and the expression of their tar-
gets, the SERT and NET, respectively, in hippocampus of P21, P28,
and adult mice.
[3H]CITALOPRAM AND [3H]NISOXETINE SATURATION BINDING IN
HIPPOCAMPUS AS A FUNCTION OF AGE
As shown in Figures 3A,C,E and Table 1, [3H]citalopram sat-
uration binding in mouse hippocampal homogenates revealed
FIGURE 2 | Effect of escitalopram and DMI to reduce time spent
immobile in theTST in male juvenile, adolescent, and adult mice.
(A) Escitalopram (10 mg/kg, sc) signiﬁcantly reduced immobility time in all
age groups. There was a signiﬁcant interaction between age and treatment
revealing that escitalopram is less effective in reducing immobility time in
P21 mice, compared with P28 or adult mice. (B) DMI (32 mg/kg, ip)
signiﬁcantly reduced immobility time in all age groups. Sample sizes were
as follows: P21, n = 38 (20 saline, 8 escitalopram, 10 DMI); P28, n = 37
(20 saline, 8 escitalopram, 8 DMI); adult mice n = 39 (20 saline, 10
escitalopram, 9 DMI). There was no main effect of route of saline
administration, so saline data were collapsed with age and drug as the only
factors; two-way ANOVA with Tukey’s post hoc tests, *P < 0.05,
**P < 0.01. Data are mean and SEM.
no signiﬁcant difference in maximal binding (Bmax) or afﬁn-
ity (Kd) values among P21 (n = 10), P28 (n = 8), and adult
(n = 9) male mice. Likewise, [3H]nisoxetine saturation binding
in mouse hippocampal homogenates revealed no signiﬁcant dif-
ference in Bmax or Kd values among P21 (n = 9), P28 (n = 9),
and adult (n = 7) male mice (Figures 3B,D,F; Table 1). Of note
is the greater variability in Kd values for [
3H]citalopram bind-
ing in P21 mice, compared with their P28 and adult counterparts
(P < 0.001, Bartlett’s test). Similarly, the variance of the Kd val-
ues for [3H]nisoxetine binding in young mice was greater than
in adults (P < 0.01, Bartlett’s test), suggesting that these young
ages may represent a transitional period where SERT and NET
are shifting toward the functional activity state of adult SERT
and NET.
Frontiers in Pharmacology | Neuropharmacology October 2013 | Volume 4 | Article 131 | 4
“fphar-04-00131” — 2013/10/25 — 11:18 — page 5 — #5
Mitchell et al. Antidepressants in juveniles and adolescents
FIGURE 3 | Specific binding of [3H]citalopram to SERT and
[3H]nisoxetine to NET in hippocampal membrane homogenates from
male P21() P28 () and adult (•) mice. Membrane preparations
were incubated with increasing concentrations of [3H]citalopram or
[3H]nisoxetine. Non-speciﬁc binding was deﬁned in the presence of
10 μM sertraline or 10 μM mazindol, respectively. Speciﬁc binding was
obtained by subtracting non-speciﬁc binding from total binding at each
ligand concentration. (A,B) Show saturation binding isotherms for binding
of [3H]citalopram or [3H]nisoxetine, respectively. Bmax and K d values for
[3H]citalopram to SERT are summarized in (C,E), and for [3H]nisoxetine
binding to NET in (D,F), respectively. For [3H]citalopram sample sizes
were as follows: P21 n = 10, P28 n = 8, adult n = 9; and for
[3H]nisoxetine, P21 n = 9, P28 n = 9, adult n = 7. Data are mean
and SEM.
RELATIONSHIP BETWEEN ANTIDEPRESSANT-LIKE EFFECT AND
SATURATION BINDING WITH [3H]CITALOPRAM AND [3H]NISOXETINE
IN HIPPOCAMPUS ACROSS AGE GROUPS
Data from Figure 2 and Table 1 are plotted in Figure 4 and
illustrate the relationship, or lack thereof, between the abil-
ity of escitalopram and DMI to produce antidepressant-like
effects in the TST and the expression and afﬁnity values for
hippocampal SERT (Figures 4A,C) and NET (Figures 4B,D).
TST data plotted in Figure 4 are the immobility times for
each individual escitalopram- or DMI-treated mouse, subtracted
from the mean value for immobility time of the same age
saline-treated mice (i.e., data from Figure 2). This difference
provides a measure of the magnitude of antidepressant-like
response that takes into account the difference in immobility
times among saline-treated mice of different ages. The abil-
ity of escitalopram to produce antidepressant-like effects in the
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Table 1 | Summary of Bmax and K d values for [3H]citalopram binding




Bmax (fmol/mgpr) 139 ± 8 180 ± 21 163 ± 17
K d (nM) 2.3 ± 0.4 1.3 ± 0.2 1.5 ± 0.1
[3H]Nisoxetine
Bmax (fmol/mgpr) 112 ± 7 143 ± 10 136 ± 23
K d (nM) 5.7 ± 0.9 7.4 ± 2.0 2.5 ± 0.8
[3H]citalopram binding n = 8–10 per group where hippocampi were from one
mouse per assay. For [3H]nisoxetine binding n = 7–9 per group, but where each
assay was from pooled hippocampi from two mice. For each ligand, there were
no signiﬁcant differences in Bmax or Kd values among ages (Kruskal–Wallis). Data
are mean and SEM.
TST increased with age, but was not associated with parallel
increases in either Bmax (Figure 4A) or afﬁnity of SERT for
[3H]citalopram (i.e., smaller Kd values; Figure 4D). The ability
of DMI to produce antidepressant-like effects did not change sig-
niﬁcantly across age groups. Likewise, Bmax and Kd values for
[3H]nisoxetine binding to NET did not vary signiﬁcantly as a
function of age.
DISCUSSION
The major ﬁndings of the present study are ﬁrst, that the SSRI esci-
talopram and the NET blocker DMI produced antidepressant-like
effects in mice as young as P21, the youngest age tested; second,
that themagnitudeof antidepressant-like response to escitalopram
increased with age but was not paralleled by increasing expression
or afﬁnity of hippocampal SERT; and third that the magnitude
of antidepressant-like response to the tricyclic, DMI, as well as
expression and afﬁnity of hippocampal NET, did not differ signif-
icantly among P21, P28, and adult mice. These ﬁndings support
the utility of juvenile mice to study antidepressant-like activity of
drugs. Moreover, our ﬁnding that juvenile mice are less sensitive to
the antidepressant-like effect of escitalopram than adults, parallels
clinical data reporting that, compared to adults, children have a
relatively poor therapeutic response to the SSRIs, ﬂuoxetine, and
FIGURE 4 | Relationship between antidepressant-like response and
hippocampal SERT and NET expression and affinity in P21, P28, and
adult male mice.The magnitude of antidepressant-like response to the SERT
blocker, escitalopram, increased with age but neither Bmax (A) nor K d (C)
values for [3H]citalopram binding to SERT varied signiﬁcantly with age. The
magnitude of antidepressant-like response to the NET blocker, DMI, as well
as Bmax (B) and K d (D) values for [
3H]nisoxetine binding to NET remained
relatively constant across ages. Data are re-plotted from Figure 2 andTable 1.
TST data from Figure 2 are plotted on the y -axis as “magnitude of
antidepressant-like response,” deﬁned as the immobility time for individual
drug-treated mice subtracted from the mean immobility time of same aged
saline-treated mice; the larger the number, the greater the antidepressant-like
effect. Sample sizes are the same as reported in legends to Figures 2,3 and
Table 1. Data are mean and SEM.
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escitalopram, the only two FDA approved antidepressants for this
young population.
In rodents, postnatal days 21–27 are considered the juvenile
period and postnatal days 28–42 equivalent to early adolescence
(Spear, 2000; Bylund and Reed, 2007). To date only a few studies
have investigated antidepressant-like activity of drugs in adoles-
cent mice and none have studied juvenile mice. Adolescent mice
(P28 or P35) were found to be sensitive to the antidepressant-like
effect of both SSRIs and tricyclics in the FST (Bourin et al., 1998;
David et al., 2001a,b; Mason et al., 2009). Only one study has used
the TST to investigate antidepressant-like activity in adolescent
mice (P35) and, as for studies using the FST, found that both
SSRIs and tricyclics were effective in reducing immobility time.
Consistent with these studies, we also found that both SSRI and
tricyclic classes of antidepressant effectively reduced immobility
time of adolescent (P28) and adult mice in the TST. Likewise, our
ﬁndings in P28 and adult mice are in good agreement with reports
in P28 and adult rats, where both SSRIs and tricyclic antidepres-
sants were effective in producing antidepressant-like activity in the
FST (Reed et al., 2008).
To our knowledge, this is the ﬁrst report of antidepressant-
like activity in P21 mice. We found that the SSRI, escitalopram,
produced antidepressant-like activity in these mice; however the
magnitude of this effect was less than that in adolescent (P28)
or adult mice. Similarly, studies using rats aged P21 in the FST,
found them to be sensitive to the antidepressant-like effects of
SSRIs, including escitalopram (Reed et al., 2008). However, in this
study a head-to-head comparison with P28 and adult rats was not
included, making it difﬁcult to draw conclusions as to whether
the magnitude of antidepressant-like effect was less in P21 rats,
compared to P28 or adult rats. Based on the present studies, where
P21, P28, and adult mice were compared head-to-head, it is clear
that the magnitude of escitalopram to produce antidepressant-like
effects in P21 mice is less than in adult mice.
We also found that P21 mice were sensitive to the
antidepressant-like effect of the tricyclic, DMI. Unlike our ﬁnding
for escitalopram, the magnitude of antidepressant-like effect of
DMI was similar among P21, P28, and adult mice. This ﬁnding
contrasts with studies using rats, where Reed et al. (2008) found
P21 rats to be insensitive to tricyclics, including DMI. Potential
reasons for these differences include species (rat versus mouse),
behavioral test (FST versus TST), drug dose, and route of admin-
istration. For example, the highest dose of DMI tested in studies
using P21 rats was 20 mg/kg (ip; Reed et al., 2008), whereas in our
studies using mice, the dose was 32 mg/kg (ip). Thus, our ability
to detect antidepressant-like effects of DMI in mice as young as
P21 may result in part from using a higher dose. Certainly, phar-
macokinetic differences between species and across ages are also a
consideration.
In the clinical setting a key difference between adult and pedi-
atric depression is response to pharmacotherapy (Hazell et al.,
1995; Kratochvil et al., 2006; Bridge et al., 2007; Bylund and Reed,
2007; Hazell andMirzaie, 2013). The present studies usingmice, as
well as published reports using rats, show that like humans, juve-
nile mice, and rats respond differently to antidepressant drugs.
While there are some apparent discrepancies in reported ﬁndings,
particularly those relating to the emergence of antidepressant-like
activity of DMI, there are numerous factors that may account for
these; some of which have been touched on already (e.g., dose,
species, test). With regard to the clinical setting, it is important
to keep in mind that therapeutic beneﬁt is also contingent upon
tolerability of the drug. Thus, although tricyclics are not approved
for use in children and adolescents, data from clinical trials have
been mixed, with some studies reporting that tricyclics lowered
depression scores in adolescents, while others found tricyclics to
be therapeutically ineffective (Hazell andMirzaie, 2013). However,
consistent with the mechanism of action of tricyclic antidepres-
sants, these drugsweremore likely thanplacebo toproduce adverse
side effects, including vertigo, tremor, low blood pressure, and
dry mouth. Thus, due to inconclusive demonstrations of thera-
peutic beneﬁt in young humans, and the possibility of harmful
side effects, or increased sensitivity to adverse side-effects in this
patient population, tricyclic antidepressants are not prescribed for
children and adolescents.
The key ﬁnding from the present study is that it is pos-
sible to detect antidepressant-like activity of drugs in mice as
young as P21. This ﬁnding opens the door for studies geared
to understanding the mechanisms underlying the relatively poor
therapeutic response of young humans to SSRIs, which in turn
paves the way for identifying treatments with improved thera-
peutic efﬁcacy. It is worth emphasizing that essentially nothing
is known about the mechanisms of antidepressant activity in
juvenile and adolescent mice. Rat studies have led the way, but
even then, knowledge is not extensive (for review, see Bylund
and Reed, 2007) with many unknowns remaining. For exam-
ple, the effect of antidepressants can be dependent on relative
rates of neurotransmitter synthesis and it is not yet known if
the activity of neurotransmitter synthesizing enzymes (e.g., tryp-
tophan hydroxylase, tyrosine hydroxylase) varies during these
postnatal periods in mice. Here, we began to investigate pos-
sible mechanisms underlying the divergent response of juvenile
mice to SSRIs and tricyclic antidepressants by ﬁrst quantifying the
expression and afﬁnity of their target proteins, SERT and NET, in
hippocampus.
Hippocampus was selected for these initial studies given its
importance in mood and antidepressant drug effects (Camp-
bell and McQueen, 2004). In rats the delayed emergence of
antidepressant-like activity of tricyclics is thought to be related
to delayed maturation of the noradrenergic system compared
with the serotonergic system (Murrin et al., 2007). As far as NET
is concerned, the primary target of DMI, its expression during
postnatal development in rat brain, measured using quantita-
tive autoradiography, is age and brain region dependent. NET
expression increases rapidly across brain regions between P10 and
P15, and attains adult levels in some regions (e.g., cortex, CA1
and CA2 regions of hippocampus, dentate gyrus, amygdala, stria-
tum) that are maintained into adulthood; in others regions (e.g.,
CA3 region of hippocampus) NET expression attains adult lev-
els at P15, but then decreases at P20 before returning to adult
levels at P25 (Sanders et al., 2005). To date there are no reports
on the development of expression of NET in mouse brain over
the postnatal ages studied here. Our data show that in hippocam-
pus, NET expression was similar in P21, P28, and adult mice.
Likewise, the afﬁnity of NET for [3H]nisoxetine was similar across
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these ages. Data from adult mouse hippocampus presented here
are in general agreement with those reported by others [e.g.,
Bmax 127 ± 5 fmol/mgpr and Kd 0.7 ± 0.05 nM, C57Bl/6 male
mice (Csölle et al., 2013)], and in adult rat cerebral cortex [Bmax
97 ± 12 fmol/mgpr and Kd 0.8 ± 0.11 nM (Tejani-Butt, 1992)].
Our data are also consistent with the quantitative autoradiography
measures of NET in rat hippocampus reported by Sanders et al.
(2005), where, with the exception of CA3 region, NET expression
did not vary across juvenile, adolescent, and adult ages. Given
that we carried out saturation binding assays in homogenates
taken from whole hippocampus it would be unlikely we would
detect any age-dependent changes in a sub-region of hippocam-
pus (such as CA3). At the expense of anatomical resolution, our
saturation binding approach afforded a measure of transporter
afﬁnity, which to our knowledge has not been previously reported
for P21 or P28 mouse or rat. Our ﬁndings in mouse hippocam-
pus show that NET expression and afﬁnity are at adult levels by
P21. Given that the antidepressant-like effects of DMI in the TST
were also similar among juvenile, adolescent, and adult mice, it
appears that NET expression and afﬁnity in hippocampus paral-
lels DMI’s antidepressant efﬁcacy in mice. It must be recognized,
however, that this does not rule out the possibility that DMI’s
antidepressant-like activity in the TST depends on NET expres-
sion in other regions. Further studies are needed to determine
the brain region(s) and mechanisms (e.g., transporters, receptors)
that mediate antidepressant-like behavioral activity in the TST
following administration of NET blockers, and how this may vary
with age.
Even less is known about the postnatal development of expres-
sion and afﬁnity of SERT in mice. Quantitative autoradiography
studies to date indicate that in rats, SERT expression reaches adult
levels between birth and P21 (Zhou et al., 2000; Galineau et al.,
2004; Bylund and Reed, 2007). Consistent with these ﬁndings in
rats, we found that SERT expression in hippocampus of P21 and
P28 mice was similar to that in adults. We also found that the
afﬁnity of hippocampal SERT for [3H]citalopram was equivalent
among P21, P28, and adult mice. To our knowledge there are
only two reports of [3H]citalopram binding using adult C57Bl/6
mouse hippocampal homogenate preparations. Our group previ-
ously reported values in good agreement with those reported here
[Bmax 171 ± 20 fmol/mgpr; Kd 1.1 ± 0.2 nM (Gould et al., 2011)].
Another group reported a higherBmax (555± 35 fmol/mgpr) but a
similarKd (1.2± 0.1 nM;Csölle et al., 2013). Of note in the present
study, even though statistical analyses did not reveal signiﬁcant
differences in afﬁnity of hippocampal SERT for [3H]citalopram
among ages, the variance of the Kd values differed signiﬁcantly
among ages. As is clear in Figure 3E, Kd values varied from 0.3
to 4.6 nM in juveniles, 0.6 to 2.1 nM in adolescents and 1.0 to
1.8 nM in adults. Thus, the spread in Kd values dropped from
4.3 nM in P21 mice, to 1.5 nM in P28 mice and to 0.8 nM
in adult mice. These data suggest that juvenile and adolescent
periods may be critical periods in development where, although
the density of SERT is at adult expression levels, the functional
activity (afﬁnity) of SERT is undergoing a transition to that of
the adult. In the case of the present data, approximately half of
P21 mice had Kd values in line with those of adults, and the
remainder had Kd values two or more fold greater (i.e., lower
afﬁnity for [3H]citalopram). Based on these initial data, it is
tempting to speculate that this variability in when the “switch”
from juvenile to adult SERT afﬁnity occurs, accounts in part
for the variability in individual response to SSRIs in pediatric
depression.
These studies are, to our knowledge, the ﬁrst to obtainBmax and
Kd values for [
3H]citaloprambinding to SERT and [3H]nisoxetine
binding to NET, two of the most prominent targets of currently
available antidepressant drugs, in juvenile and adolescent mice,
and the results are in agreement with the few existing reports from
adult mice (Gould et al., 2011; Csölle et al., 2013). The present
ﬁndings raise the possibility that, although SERT expression may
be at or near adult levels in P21 mice, the large variability in afﬁn-
ity state of SERT for SSRIs may account, at least in part, for the
lower clinical effectiveness of SSRIs in children. Showing that the
TST is a relevant behavioral assay of antidepressant-like activity in
juvenile (P21) and adolescent (P28) mice, sets the stage for future
studies of the mechanisms underlying the antidepressant response
in these young populations.
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